| 763798 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
313 Stealthier mutanomes are induced after nivolumab immunotherapy |
2021-11-01 |
10.1136/jitc-2021-sitc2021.313 |
Richard Guilhem, Princiotta Michael, Steinberg Gary, Martin William, Groot Anne de |
| 763797 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
428 Preliminary clinical results of toripalimab monotherapy or combination therapy for recurrent or refractory gynecologic cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.428 |
Diao Peng, Peng Qian, Luo Xingbo, Huang Qing, Yan Gaoshu, Tan Yan |
| 763796 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
135 Identification and characterization of an allogeneic iNKT-CAR targeting BCMA |
2021-11-01 |
10.1136/jitc-2021-sitc2021.135 |
Michelet Xavier, Chantzoura Eleni, Altman-Sharoni Efrat, Popis Martyna, Masakyan Reed, Ibbett Paul, Wright Deborah, Rossi Moira Pinzan, Dijk Marc Van |
| 763795 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
198 Costimulatory antigen receptor (CoStAR): a novel platform that enhances the activity of tumor infiltrating lymphocytes (TILs) |
2021-11-01 |
10.1136/jitc-2021-sitc2021.198 |
Sukumaran Sujita, Kalaitsidou Milena, Mojadidi Michelle, Yarka Clare, Ouyang Yong (Stella), Gschweng Eric, Kueberuwa Gray, Bridgeman John, Hawkins Bob, Alvarez-Rodríguez Rubén |
| 763794 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
214 SIRPα-deficient macrophages activate polyclonal tissue-resident cytotoxic CD8 T cells to eliminate irradiation-refractory non-small cell lung carcinoma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.214 |
Bian Zhen, Shi Lei, Kidder Koby, Liu Yuan |
| 763793 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
19 Exome-scale liquid biopsy characterization of emerging immune resistance mechanisms in treatment-resistant GIST |
2021-11-01 |
10.1136/jitc-2021-sitc2021.019 |
Abbott Charles, Coleman Niamh, Wang Jing, Northcott Josette, Navarro Fabio, McDaniel Lee, Levy Eric, Pyke Rachel, Janku Filip, Chen Richard, Boyle Sean |
| 763792 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.529 |
Cutsem Eric Van, Prenen Hans, Delafontaine Brant, Spencer Kristen, Mitchell Tara, Burris Howard, Kotecki Nuria, Kristeleit Rebecca, Pinato David, Sahebjam Solmaz, Graham Donna, Karasic Thomas, Daniel Jeannie, O’Hayer Kevin, Geschwindt Ryan, Piha-Paul Sarina |
| 763791 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
468 A phase 2 study of toripalimab plus anlotinib as maintenance therapy in extensive-stage small cell lung cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.468 |
Lv Dongqing, Wu Guixian |
| 763790 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
497 A Study of ALPN-202, a PD-L1-dependent CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in patients with advanced malignancies |
2021-11-01 |
10.1136/jitc-2021-sitc2021.497 |
Lakhani Nehal, McKean Meredith, Patnaik Amita, Manjarrez Kristi, Zayed Hany, Chisamore Michael, Peng Stanford, Goldberg Zelanna |
| 763789 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
366 Combined exploratory immunophenotyping and transcriptomic tumor analysis in patients treated with OSE2101 vaccine in HLA-A2+ advanced non-small cell lung cancer (NSCLC) from the ATALANTE-1 trial |
2021-11-01 |
10.1136/jitc-2021-sitc2021.366 |
Viteri Santiago, Hilgers Werner, Denis Fabrice, Quoix Elisabeth, Robinet Gilles, Felip Enriqueta, Dziadziuszko Rafal, Poirier Nicolas, Fromond Claudia, Girault Isabelle, Vandewalle Thomas, Costantini Dominique, Vasseur Bérangère, Cappuzzo Federico, Giaccone Giuseppe, Besse Benjamin |
